To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Europe | European ＆ international partnerships | Vaccine | Virus
Pan-Ebola Vaccine Innovative Approach
PEVIA - Pan-Ebola Vaccine Innovative Approach - is a collaborative research programme aiming to develop and to bring to the clinics an innovative pan-Ebola vaccine, safe and effective against multiple Ebola virus strains and ease to produce and deploy in endemic regions.
The overall objective of PEVIA is to bring this new pan-Ebola vaccine up to a stage ready for testing in an outbreak setting by comprehensively analyzing their immunological and safety profile in human using cutting-edge technologies. The project, officially kicked off June 1st 2017, also addresses the development innovative functional analysis tools to accelerate the development of new vaccine candidates against Ebola virus and Filovirus as well as novel diagnostic tests that can be readily deployed in the field. PEVIA project will have a significant impact on global health, both at the individual and the public health levels, and will increase the readiness to respond to future outbreaks of Ebola and other filoviral haemorrhagic.
PEVIA is a public-private consortium made up of 13 partners involving 3 small and medium enterprises (SMEs), and experts from 10 academic institutions, including scientists of two BSL-4 laboratories and four clinical centers (France, Switzerland, Benin, Tanzania).
PEVIA is a 6 years project started in June 2017 and funded by the Innovative Medicine Initiative 2 Joint Undertaking (IMI 2 JU).
Joliot institute contacts: Bernard Maillère (firstname.lastname@example.org) et Laurent Bellanger (email@example.com)
ABOUT IMI - INNOVATIVE MEDICINES INITIATIVE
IMI is the world's largest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations).
The objective of IMI, particularly in its second phase (IMI2, 2014-2020), is to develop new generation vaccines, drugs and treatments, such as new antibiotics.
For more information: https://www.imi.europa.eu/
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.